Patent Assignment
Reel/Frame 054539/0641
Assignment of Assignor's Interest
Recorded: 2020-12-03
Pages: 3
Assignee
MOLECULAR SKIN THERAPEUTICS, INC.
421 KIPLING STREET, PALO ALTO, CALIFORNIA, 94301
Covered Property
(1)
Benzoxazinone Compounds as KLK5/7 Dual Inhibitors
Patent:
11,643,420 →
Application:
17/037,910 →
Publication:
US 2021/0101911
PCT:
PCT/US2020/053369 ↗
Related Assignments
(3)
Other recorded transfers of the patent in this record — the chain of ownership.
Security Interest
Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
Security Interest
Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
Release of Security Interest in Patent Collateral
Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.
Reel/Frame 070551/0095 →